Jenny Bergqvist

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: BRITISH JOURNAL OF CANCER. 2023;129(1):61-71

Side effects of low-dose tamoxifen: results from a six-armed randomised controlled trial in healthy women.

Hammarström M; Gabrielson M; Crippa A; Discacciati A; Eklund M; Lundholm C; Bäcklund M; Wengström Y; Borgquist S; Bergqvist J; Eriksson M; Tapia J; Czene K; Hall P
Article: INTERNATIONAL JOURNAL OF CANCER. 2023;152(11):2362-2372

Effects of tamoxifen on normal breast tissue histological composition: Results from a randomised six-arm placebo-controlled trial in healthy women.

Gabrielson M; Hammarström M; Bäcklund M; Bergqvist J; Lång K; Rosendahl AH; Borgquist S; Hellgren R; Czene K; Hall P
Article: SUPPORTIVE CARE IN CANCER. 2022;30(9):7721-7730

Equal receipt of specialized palliative care in breast and prostate cancer: a register study.

Bergqvist J; Hedman C; Schultz T; Strang P
Article: ONCOLOGIST. 2022;27(7):e597-e600

Topical Endoxifen for Mammographic Density Reduction-A Randomized Controlled Trial.

Bäcklund M; Eriksson M; Gabrielson M; Hammarström M; Quay S; Bergqvist J; Hellgren R; Czene K; Hall P
Article: CANCERS. 2021;13(15):3707

'Palliative-D'-Vitamin D Supplementation to Palliative Cancer Patients: A Double Blind, Randomized Placebo-Controlled Multicenter Trial.

Helde Frankling M; Klasson C; Sandberg C; Nordström M; Warnqvist A; Bergqvist J; Bergman P; Björkhem-Bergman L
Article: SUPPORTIVE CARE IN CANCER. 2021;29(1):491-497

Patient interactive digital support for women with adjuvant endocrine therapy in order to increase compliance and quality of life.

Bergqvist J; Lundström S; Wengström Y
Article: JOURNAL OF PALLIATIVE MEDICINE. 2020;23(1):67-73

The Impact of Integrated Home Palliative Care Services on Resource Use and Place of Death.

Bergqvist J; Ljunggren G
Article: JOURNAL OF PAIN AND SYMPTOM MANAGEMENT. 2019;57(4):746-752

Breast Cancer Patients' Preferences for Truth Versus Hope Are Dynamic and Change During Late Lines of Palliative Chemotherapy.

Bergqvist J; Strang P
Article: JOURNAL OF NEURO-ONCOLOGY. 2018;139(3):599-608

The effects of clinical and sociodemographic factors on survival, resource use and lead times in patients with high-grade gliomas: a population-based register study.

Bergqvist J; Iderberg H; Mesterton J; Henriksson R
Article: BMJ SUPPORTIVE & PALLIATIVE CARE. 2017;7(4):458-463

Vitamin D supplementation to palliative cancer patients: protocol of a double-blind, randomised controlled trial 'Palliative-D'.

Helde-Frankling M; Bergqvist J; Klasson C; Nordström M; Höijer J; Bergman P; Björkhem-Bergman L
Article: ACTA ONCOLOGICA. 2017;56(10):1258-1264

Does palliative chemotherapy provide a palliative effect on symptoms in late palliative stages? An interview study with oncologists.

Strang P; Bergqvist J
Article: ACTA ONCOLOGICA. 2017;56(9):1168-1174

The will to live - breast cancer patients perceptions' of palliative chemotherapy.

Bergqvist J; Strang P
Article: ACTA ONCOLOGICA. 2017;56(3):405-414

Healthcare resource use, comorbidity, treatment and clinical outcomes for patients with primary intracranial tumors: a Swedish population-based register study.

Bergqvist J; Iderberg H; Mesterton J; Bengtsson N; Wettermark B; Henriksson R
Article: PLOS ONE. 2017;12(8):e0184208

Vitamin D supplementation to palliative cancer patients shows positive effects on pain and infections-Results from a matched case-control study.

Helde-Frankling M; Höijer J; Bergqvist J; Björkhem-Bergman L
Article: CANCERS. 2016;8(9):E84-84

Antibiotic Treatment in End-of-Life Cancer Patients-A Retrospective Observational Study at a Palliative Care Center in Sweden.

Helde-Frankling M; Bergqvist J; Bergman P; Björkhem-Bergman L
Article: PLOS ONE. 2015;10(5):e0128223

Low vitamin D levels are associated with higher opioid dose in palliative cancer patients--results from an observational study in Sweden.

Bergman P; Sperneder S; Höijer J; Bergqvist J; Björkhem-Bergman L
Article: BREAST CANCER RESEARCH AND TREATMENT. 2013;139(3):751-758

Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial.

Bjöhle J; Bergqvist J; Gronowitz JS; Johansson H; Carlsson L; Einbeigi Z; Linderholm B; Loman N; Malmberg M; Söderberg M; Sundquist M; Walz TM; Fernö M; Bergh J; Hatschek T
Article: FAMILIAL CANCER. 2010;9(3):263-265

RASSF1A polymorphism in familial breast cancer.

Bergqvist J; Latif A; Roberts SA; Hadfield KD; Lalloo F; Howell A; Evans DG; Newman WG
Article: MEDICAL ONCOLOGY. 2009;26(4):480-490

Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor.

Linderholm B; Bergqvist J; Hellborg H; Johansson U; Linderholm M; von Schoultz E; Elmberger G; Skoog L; Bergh J
Article: ANNALS OF ONCOLOGY. 2007;18(5):845-850

Quantitative real-time PCR analysis and microarray-based RNA expression of HER2 in relation to outcome.

Bergqvist J; Ohd JF; Smeds J; Klaar S; Isola J; Nordgren H; Elmberger GP; Hellborg H; Bjohle J; Borg A-L; Skoog L; Bergh J
Article: EUROPEAN JOURNAL OF CANCER. 2006;42(8):1104-1112

Activated ERK1/2 and phosphorylated oestrogen receptor alpha are associated with improved breast cancer survival in women treated with tamoxifen.

Bergqvist J; Elmberger G; Ohd J; Linderholm B; Bjohle J; Hellborg H; Nordgren H; Borg A-L; Skoog L; Bergh J
Article: ANNALS OF ONCOLOGY. 2005;16(5):743-748

Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF.

Andersson J; Larsson L; Klaar S; Holmberg L; Nilsson J; Inganäs M; Carlsson G; Ohd J; Rudenstam C-M; Gustavsson B; Bergh J
Article: APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY. 2004;12(1):14-20

HER-2/neu (c-erbB-2) evaluation in primary breast carcinoma by fluorescent in situ hybridization and immunohistochemistry with special focus on intratumor heterogeneity and comparison of invasive and in situ components.

Andersson J; Linderholm B; Bergh J; Elmberger G
Article: EUROPEAN JOURNAL OF CANCER. 2004;40(1):33-42

Overexpression of c-erbB-2 is related to a higher expression of vascular endothelial growth factor (VEGF) and constitutes an independent prognostic factor in primary node-positive breast cancer after adjuvant systemic treatment.

Linderholm B; Andersson J; Lindh B; Beckman L; Erlanson M; Edin K; Tavelin B; Grankvist K; Henriksson R
Article: ACTA ONCOLOGICA. 2002;41(3):276-281

A population-based study on the first forty-eight breast cancer patients receiving trastuzumab (Herceptin) on a named patient basis in Sweden.

Andersson J; Linderholm B; Greim G; Lindh B; Lindman H; Tennvall J; Tennvall-Nittby L; Pettersson-Sköld D; Sverrisdottir A; Söderberg M; Klaar S; Bergh J
Visa fler

Alla övriga publikationer

Corrigendum: BREAST. 2008;17(3):319

"How to treat male breast cancer" (vol 16S2, pg S147, 2007)

Czene K; Bergqvist J; Hall P; Bergh J
Published conference paper: BREAST. 2007;16 Suppl 2:S147-S154

How to treat male breast cancer.

Czene K; Bergqvist J; Hall P; Bergh J
Published conference paper: ACTA ONCOLOGICA. 2000;39(3):319-326

Can axillary dissection be avoided by improved molecular biological diagnosis?

Lindahl T; Engel G; Ahlgren J; Klaar S; Bjöhle J; Lindman H; Andersson J; von Schoultz E; Bergh J

Anställningar

Anknuten till Forskning, Medicinsk epidemiologi och biostatistik, Karolinska Institutet, 2023-2024
Anknuten till Forskning, Medicinsk epidemiologi och biostatistik, Karolinska Institutet, 2022-2024

Examina och utbildning

Docent, onkologi, Karolinska Institutet, 2020
MEDICINE DOKTORSEXAMEN, Institutionen för onkologi-patologi, Karolinska Institutet, 2006

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI